Ahmet Özderya

Dr. Ahmet Özderya

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in Archives of Medical Science
Verified
Journal Article
Open access
TKTeoman Kilic
Teoman Kilic
AIAlfonso Ielasi
Alfonso Ielasi
VNVlasis Ninios
Vlasis Ninios
LKLevent Korkmaz
Levent Korkmaz
DPDemosthenes Panagiotakos
Demosthenes Panagiotakos
AAAli Rıza Akyüz
Ali Rıza Akyüz
Introduction: Limited data exist on long-term follow-up of severe aortic stenosis (SAS) patients who have undergone transcatheter aortic valve implantation (TAVI) with a new generation, balloon expandable Myval transcatheter heart valve (THV). Thus, we sought to investigate the performance and 2-year clinical outcome of the Myval THV system based on Valve Academic Research Consortium-3 (VARC-3) criteria.Material and methods: A multi-centre, registry-based, observational study was conducted, which included 207 consecutive degenerative SAS patients, from Turkey (n = 128), Italy (n = 58), and Greece (n = 21) (mean [standard deviation] 81 (7) years, 94 [45%] men; 73% NYHA III or IV; EuroSCORE II 5.2% [2.4%]); all patients underwent TAVI with Myval. Patients were followed up at 1 year and 2 years after implantation. Clinical and procedural outcomes were defined according to VARC-3 criteria.Results: Technical success was observed in 204 (99%), device success was observed in 189 (91%), early safety was observed in 161 (78%), and clinical efficacy was observed in 163 (79%) patients. The 30-day death rate was 7.7%; of these, 3.4% were due to cardiovascular reasons. All-cause and cardiovascular mortality rates were 9.7% and 4.3% at 1-year follow-up, and 17.4% and 9.7% at 2-year follow-up, respectively. Incidence of ≥ moderate paravalvular leak (PVL) at 30 days, 1 year and 2 years of follow-up were 3.4%, 4.3% and 4.8%. A total of 11.1% of patients required a permanent pacemaker implantation (PPI) at 30 days after implantation, while the cumulative rate of PPI at 2 years was 12.1%.Conclusions: In this cohort of patients with SAS, the Myval was found to be safe and effective in up to 2 years of follow-up.

30 August 2022 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
MSMuhammet Raşit Sayın
Muhammet Raşit Sayın
AÖAhmet Özderya
Ahmet Özderya
AKAli Hakan Konuş
Ali Hakan Konuş
MYMurat Gökhan Yerlikaya
Murat Gökhan Yerlikaya
MMMehmet Ali Maz
Mehmet Ali Maz
FKFaruk Kara
Faruk Kara
Aim The objectives of this study were to determine the relationship between the systemic immune-inflammation index (SII) and new onset atrial fibrillation (NOAF) in patients with acute coronary syndrome (ACS), and to assess the use of this relation, if any, to predict NOAF in the context of ACS Material and Methods A total of 622 patients diagnosed with ACS and followed up between September 2019 and September 2021 were included in this study. 35 (5.6 %) of these patients, suffering from NOAF, were designated as the patient group, and the remaining 577 (94.4 %) patients were designated as the control group. SII was calculated with the formula [ (platelet count x neutrophil count) / lymphocyte count] in all patients. Results SII was significantly increased in the NOAF group [1641 (778-4506) vs. 660 (54-2835); p<0.001. The multivariable logistic regression analysis revealed that SII [OR: 1.002, 95 %CI: 1.001–1.002, p<0.001] is one of the independent predictors for NOAF, in addition to age (p=0.003) and left atrium size (p=0.005). Conclusion The SII index is an independent predictor of NOAF in ACS patients. This index can be used as an easily accessible value in the clinic. Assessment of risk factors for NOAF may permit early treatment and close follow-up of patients with poor prognosis who may develop AF.

1 January 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
AOAhmet Oz
Ahmet Oz
KTKenan Toprak
Kenan Toprak
EAErtan Aydın
Ertan Aydın
İSİbrahim Saraç
İbrahim Saraç
MDMustafa Dogdus
Mustafa Dogdus
MZMehdi Zoghi
Mehdi Zoghi
Background Dual antiplatelet therapy (DAPT) is the treatment of choice for patients with acute and chronic coronary syndromes as it reduces mortality and prevents recurrent thrombotic complications. The assessment of both ischaemic burden and bleeding risk is crucial in deciding which DAPT to choose and how long it should be continued. Objectives The aim of our study was to perform prospective clinical follow-up of patients receiving fixed-dose combination therapy (ASA 75 mg + clopidogrel 75 mg). Our study is a multicentric, cross-sectional, observational, cohort study. Methods A total of 1500 patients who were started on fixed-dose combination DAPT for acute or chronic coronary syndrome were included in the study. Primary endpoints were hospitalization for any reason, hospitalization for cardiovascular cause, acute myocardial infarction, stent thrombosis, target vessel revascularization and bleeding; the secondary endpoints were death for any reason or cardiovascular cause and stroke. The significance level adopted in the statistical analysis was 5%. Results Median age was 63 years; 78.5% of the patients were receiving DAPT treatment for acute coronary syndrome. The rates of hospitalization for cardiovascular reasons, acute myocardial infartion, stent thrombosis and target-vessel revascularization were 7.9%, 2.3%, 1.3% and 4.2%, respectively. While the rate of BARC type 1 bleeding was 3.3%, the rate of BARC type 5, 3, or 2 bleeding was 0.6%. The secondary endpoints which were death from any cause, cardiovascular death and stroke were 0.5%, 0.3% and 0.3%, respectively. Conclusion: Our study shows that fixed-dose combination therapy is effective and safe in appropriately selected patients with acute or chronic coronary syndromes.

30 March 2025 in Biomarkers in Medicine
Verified
Journal Article
Closed access
AYAbdullah Yıldırım
Abdullah Yıldırım
ÖGÖmer Genç
Ömer Genç
MEMert Evlice
Mert Evlice
AEAslan Erdoğan
Aslan Erdoğan
EPEmre Pacaci
Emre Pacaci
IKIbrahim Halil Kurt
Ibrahim Halil Kurt
This retrospective, multi-center study evaluates the relationships between novel liver function scoring systems - Albumin-Bilirubin (ALBI) score, EZ-ALBI, PALBI, and MELD-XI - and outcomes in patients undergoing transcatheter aortic valve implantation (TAVI). Feature importance was assessed with SHAP-values via the XGBoost-algorithm. The ALBI score exhibited the strongest association with 30-day mortality after TAVI (AUC = 0.723, p < 0.001), outperforming other scores in this regard and consistently demonstrating predictive power across various subgroup populations. Higher 30-day mortality rates were observed in the higher tertiles of the ALBI score compared to the lower tertiles (log-rank p-value = 0.004). The ALBI-based nomogram (C-index = 0.81, 95% CI:0.73-0.86, p = 0 < 001) demonstrated superior predictive power for 30-day mortality post-TAVI compared to the STS (C-index = 0.71, 95% CI :0.64-0.77, p = 0 < 001). In addition, the nomogram showed a significant improvement in reclassification (69.3%, p < 0.001) and a stronger discrimination 15.2%, p < 0.001) compared to the STS. It integrates nine variables, first ALBI score (SHAP:1.165), including NYHA class (0.594), body mass index (0.510), glomerular filtration rate, creatinine, hemoglobin, gender, predilatation requirement, presence of chronic kidney disease, and providing a comprehensive risk assessment tool. This study exhibits the significance of liver dysfunction with AS patients and suggests incorporating liver function parameters in pre-operative risk assessments for better clinical outcomes in TAVI procedures.

1 January 2024 in Advances in Interventional Cardiology
Verified
Journal Article
Open access
AÖAhmet Özderya
Ahmet Özderya
MTMuhammed Tekbil
Muhammed Tekbil
NENurel Ertürk
Nurel Ertürk
MMMehmet A. Maz
Mehmet A. Maz
MYMurat G. Yerlikaya
Murat G. Yerlikaya
MSMuhammet R. Sayın
Muhammet R. Sayın
Introduction: Obesity is one of the main reversible causes of coronary artery disease. Aim: To investigate the relationship between body component measurements calculated with TANITA and SYNTAX score (SXscore), which indicates coronary complexity. Material and methods: 200 acute...

1 January 2024 in Advances in Interventional Cardiology
Verified
Journal Article
Open access
AÖAhmet Özderya
Ahmet Özderya
MYMurat G. Yerlikaya
Murat G. Yerlikaya
AAAhmet O. Aslan
Ahmet O. Aslan
AKAli H. Konuş
Ali H. Konuş
SŞSinan Şahin
Sinan Şahin
AAAli R. Akyüz
Ali R. Akyüz
Introduction: One of the predictable and preventable complications that may occur after transaortic valve implantation (TAVI) is the requirement for permanent pacemaker (PPM) implantation. Aim: To evaluate the relationship between aortic knob calcification (AKC) assessed by preoperative...